Future therapy of hepatitis C

Hepatology

Volumn 36, Issue 5 I, 2002, Pages

  McHutchison, John G ^a   Patel, Keyur ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; BARBITURIC ACID DERIVATIVE; CIVACIR; GAMMA INTERFERON; HELICASE; HEPATITIS VACCINE; HISTAMINE; IMMUNOMODULATING AGENT; INOSINATE DEHYDROGENASE INHIBITOR; INTERFERON; ISIS 14803; JTK 003; LEVOVIRIN; LIPOSOME; MERIMEPODIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; POLYPROTEIN; PROTEINASE INHIBITOR; RHODANINE; RIBAMIDINE; RIBAVIRIN; RNA POLYMERASE; RPI 13919; SERINE PROTEINASE; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VP 50406;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CRYSTALLOGRAPHY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TRANSLATION INITIATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GASTROENTEROLOGY; HEPATITIS C; HUMANS;

EID: 0036830350     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.36795     Document Type: Conference Paper

References (24)

1. Lau JYN, Standring DN. Development of novel therapies for hepatitis C. In: Liang TJ, Hoofnagle JH, eds. Hepatitis C: Biomedical Research Reports. 1st Ed. London, Academic Press, 2000;453-467.
2. Dymock BW. Emerging therapies for hepatitis C virus infection. Emerg Drugs 2001;6:13-42.
3. Mercer DF, Schiller DE, Elliot JF, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-933.
4. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
5. Pockros PJ. Developments in treatment of chronic hepatitis C. Expert Opin Invest Drugs 2002;11:1-14.
6. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-1009
7. Lin C-C, Luu K, Lourenco D, Corritori S, Hong Z, Lau JY. Viramidine, a prodrug of ribavirin, demonstrated superior liver-targeting properties and much improved toxicity profile in cynomolgus monkey studies [Abstract]. Hepatology 2001;34(Suppl.):453A.
8. Lau JY, Lin C-C. Assessment of liver delivery of ribavirin and viramidine, a liver-targeting ribavirin prodrug, using whole body autoradiography [Abstract]. Hepatology 2001;34(Suppl.):427A.
9. McHutchison JG, Cheung R, Shiffman ML, Wright T, Gordon SC, Knox SJ, Ette E, et al. A 4-week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously untreated patients with chronic hepatitis C [Abstract]. Hepatology 2001;34(Suppl.):329A.
10. Afdhal N, Flamm S, Imperial JC, Malet PF, Tong M, Herrine SK, Brown Jr R, et al. Analyses of 40 KDA peginterferon alfa-2a in combination with ribavirin, mycophenolate mofetil, amantadine or amantadine plus ribavirin in patients that relapsed or did not respond to Rebetron therapy: A report of two randomized, multicenter, efficacy and safety studies [Abstract]. Hepatology 2001;34(Suppl.):243A.
11. Lurie Y, Pakula R, Malnick S, Beer-Gabel M, Gehlsen KR. Efficacy and safety of the combination of histamine dihydrochloride and interferon alpha-2b in a phase II trial in naive patients with chronic hepatitis C [Abstract]. Hepatology 2001;34(Suppl.):350A.
12. Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: A magic bullet or yet another dead duck. J Hepatol 2001;35:527-530.
13. Bartenschlager R, Lohmann V, Replication of hepatitis C virus. J Gen Virol 2000;81:1631-1648.
14. Steinkuhler C, Koch U, Narjes F, Matassa VG. Hepatitis C virus serine protease inhibitors: Current progress and future challenges. Curr Med Chem 2001;8:919-932.
15. Myles DC. Recent advances in the discovery of small molecule therapies for HCV. Curr Opin Drug Discov Devel 2001;4:411-416.
16. Zhang X. Inhibitors of hepatitis C: A review of the recent patent literature. Drugs 2002;5:154-158.
17. Witherell GW. ISIS-14803 (ISIS Pharmaceuticals). Curr Opin Invest Drugs 2001;2:1523-1529.
18. McHutchison JG, Pockros P, Nyberg LM, Kwoh TJ, Dorr FA. A dose escalation study of ISIS 14803, an antisense inhibitor of HCV, in chronichepatitis C patients [Abstract]. Hepatology 2001;34 (Suppl.):350A.
19. Lee PA, Blatt LM, Blanchard KS, Bouhana KS, Pavco PA, Bellon L, Sandberg JA. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 2000;32:640-646.
20. Reeves HL, Friedman SL. Activation of hepatic stellate cells: A key issue in liver fibrosis. Front Biosci 2002;7:808-826.
21. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, et al. Interferon-gamma inhibits replicaton of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002;35:694-703.
22. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Lutz-Henning B. A preliminary study of long-term treatment with interferon gamma-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-1269.
23. Nelson D, Soldevila-Pico C, Abdelmalek M, Xu Y, Sampson D, Kao KJ, Davis G. Long-term use of recombinant interleukin 10 (IL-10) in patients with advanced chronic hepatitis C: Insight into immunopathogenesis [Abstract]. Hepatology 2001;34(Suppl.):430A.
24. Di Bisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002;35:224-231.